Repositioning Candidate Details
| Candidate ID: | R0316 |
| Source ID: | DB00870 |
| Source Type: | approved; withdrawn |
| Compound Type: | small molecule |
| Compound Name: | Suprofen |
| Synonyms: | (±)-2-(p-(2-thenoyl)phenyl)propionic acid; 2-[4-(Thiophene-2-carbonyl)-phenyl]-propionic acid; p-2-thenoylhydratropic acid; Suprofen; Sutoprofen; α-methyl-4-(2-thienylcarbonyl)benzeneacetic acid |
| Molecular Formula: | C14H12O3S |
| SMILES: | CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1 |
| Structure: |
|
| DrugBank Description: | An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States. |
| CAS Number: | 40828-46-4 |
| Molecular Weight: | 260.308 |
| DrugBank Indication: | Used as eye drops to inhibit the miosis (pupil constriction) that may occur during ocular surgery. |
| DrugBank Pharmacology: | Suprofen is a non-steroidal anti-inflammatory analgesic and antipyretic. Ophthalmic anti-inflammatory medicines are used in the eye to lessen problems that can occur during or after some kinds of eye surgery. Sometimes, the pupil of the eye gets smaller during an operation (pupil constriction), making it more difficult for the surgeon to reach some areas of the eye. Suprofen is used to help prevent this. |
| DrugBank MoA: | Suprofen binds to the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes, preventing the synthesis of prostaglandins and reducing the inflammatory response. Cyclooxygenase catalyses the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A<sub>2</sub>). Prostaglandins act (among other things) as messenger molecules in the process of inflammation. The overall result is a reduction in pain and inflammation in the eyes and the prevention of pupil constriction during surgery. Normally trauma to the anterior segment of the eye (especially the iris) increases endogenous prostaglandin synthesis which leads to constriction of the iris sphincter. |
| Targets: | Prostaglandin G/H synthase 1 inhibitor; Prostaglandin G/H synthase 2 inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|